Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 12.90p 12.80p 13.00p 12.90p 12.90p 12.90p 9,114 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.6 -4.2 - 12.03

Evgen Pharma Share Discussion Threads

Showing 526 to 549 of 550 messages
Chat Pages: 22  21  20  19  18  17  16  15  14  13  12  11  Older
DateSubjectAuthorDiscuss
22/2/2018
12:04
http://www.capitalnetwork.com/companies/research/110586/evgen-pharma-plc-harnessing-sulforaphane-s-therapeutic-properties-110586.html
ohisay
30/1/2018
11:19
I think it will slip below the 12p placing price as the placing shares are flipped for a nice profit especially with full trial readout not for another 11 months
lambo222
30/1/2018
09:30
Slipping back to floor support levels, good price to buy in ahead of next RNS.
rathean
15/1/2018
13:09
The Breast Cancer conference has a PDF available on it's website. The poster information is on page 80 hTTp://breastcancerconference.org/wp-content/uploads/2018/01/UK-IBCS-Published-Abstracts.pdf On the same page is a study by AstraZeneca doing a similar study with Progesterone receptor antagonists to inhibit cancer stem cell activity. I would be interested to know how they compare.
pdt
15/1/2018
07:39
More scientific evidence released today by the company supporting their Breast cancer treatment. I think the Hardman report estimated the market for this treatment at $5 billion per annum. Look forward to the interim phase II read out by June this year. Early signs are that it works and increasingly they are providing the science of why it works. Hugely important to breast cancer patients.
pdt
12/1/2018
20:29
Another study showing the effectiveness against cancer stem cells; "Sulforaphane reverses gefitinib tolerance in human lung cancer cells via modulation of sonic hedgehog signaling" hTTps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738694/ Gefitinib is marketed by Astrazeneca under the trade name Iressa. Currently doing $500m per annum in sales.
pdt
12/1/2018
11:41
Chart suggests we're just off the bottom. Any positive news will see it 25p again.
rathean
05/1/2018
20:35
3.4m shares still need to be declared
dave444
04/1/2018
09:31
Surprised that no holding statements have been declared after fundraising
dave444
13/12/2017
10:16
Agreed #Tilly99, share price discounts huge upside. Great entry point, it'll rise quickly when it goes
rathean
13/12/2017
08:50
Floated at 37p? And only had good news since
tilly99
13/12/2017
08:35
Dave Doubt it!!All time low and great collaborations !
tilly99
13/12/2017
07:33
Great news about Kings and Stroke. Here is some published information on their work with sulforaphane and stroke hTTp://onlinelibrary.wiley.com/doi/10.1113/jphysiol.2013.257964/full
pdt
12/12/2017
20:51
Could also be 12p!
dave444
11/12/2017
11:06
Great piece from EvgDave you could be right!! 100p wow
tilly99
11/12/2017
11:01
Just goes to show there are no slam dunks in the biotech business. The researchers in this COPD trial sound utterly bewildered by the result, but all credit to them for publishing... http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0163716
supernumerary
11/12/2017
09:36
RNS 3rd party research RNS stating Evgen phase two trials now fully funded with results expected later in 2018.
rathean
10/12/2017
13:00
1pd?Really? Wow
tilly99
09/12/2017
13:51
I would not be surprised if it hit 12p but a £1/share price would not surprise me by February
dave444
09/12/2017
13:25
Dave444Price tgt?
tilly99
09/12/2017
10:37
I see they now have two live recruiting sites in Belgium, one in Spain and four in the UK. With others listed in France, Spain and the UK which are not yet recruiting. Looks like they will hit their date of end of 2018 for metastatic breast cancer. However, I would expect them to tie up a licence deal long before then. Possibly even before the H1 2018 interim read out. There should be good newsflow in 2018 with other activities and third party investigations. I did see MS was not mentioned but Stroke (other than subarachnoid) and Brain cancer seem to be new?
pdt
08/12/2017
16:58
Clearly a placing would hav that impact smart ass!!
dave444
08/12/2017
16:49
dave444 5 Dec '17 - 08:12 - 89 of 95 0 0 Well just had a small top up as 15p seems to be as low as it goes dave444 6 Dec '17 - 08:35 - 92 of 95 0 0 Should be a good run up to Xmas >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Obviously not!
papillon
08/12/2017
12:47
Rathean - agreed. That was the section I was going to cut and paste. Excellent news on nearly 12 month disease free progression for one person and others over 24 week disease free progression. This is a hugely valuable market. $5 billion per annum I believe was mentioned in the Hardman report. And an amazing scientific breakthrough potentially turning metastatic breast cancer from a death sentence to a manageable condition. As Stephen Franklin was quoted in The Times article recently. This will literally save/extend hundreds of thousands of lives. And good news on resolving the funding which was hanging over the company. Only disappointing news I saw was that the stroke trial has probably been delayed a few months. I think the phrase is now "around year end" to finish.
pdt
Chat Pages: 22  21  20  19  18  17  16  15  14  13  12  11  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180225 06:14:15